The federal standard for 7-hydroxymitragynine in kratom products was initially recommended at a concentration cap of 0.05 percent

Drug pricing and affordability, FDA drug approvals, clinical trial design, drug shortages, insurer coverage, pharmaceutical regulation, and medication access.